MedPath
FDA Approval

Ezetimibe

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
May 25, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ezetimibe(10 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Preferred Pharmaceuticals Inc.

791119022

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Preferred Pharmaceuticals Inc.

Preferred Pharmaceuticals Inc.

Preferred Pharmaceuticals Inc.

791119022

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ezetimibe

Product Details

NDC Product Code
68788-8297
Application Number
ANDA209234
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
May 25, 2023
EzetimibeActive
Code: EOR26LQQ24Class: ACTIBQuantity: 10 mg in 1 1
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48Class: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
SODIUM LAURYL SULFATEInactive
Code: 368GB5141JClass: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WOClass: IACT
CROSPOVIDONE (120 .MU.M)Inactive
Code: 68401960MKClass: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61UClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
© Copyright 2025. All Rights Reserved by MedPath